Clinical Trials Browser

Has results × osimertinib × Clear all

NCT03831932 2026-04-13

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

22 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06303167 2026-04-13

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Phase 2 Active not recruiting

19 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT02511106 2026-03-30

ADAURA

Phase 3 Active not recruiting

682 enrolled 20 charts 3 FDA

Stage IB-IIIA Non-small Cell Lung Carcinoma

NCT03433469 2026-03-30

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

Phase 2 Active not recruiting

27 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT02971501 2026-03-17

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Phase 2 Active not recruiting

7 enrolled 9 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03381274 2026-03-11

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Phase 1/2 Active not recruiting

43 enrolled 30 charts

Carcinoma, Non-Small-Cell Lung

NCT03521154 2026-02-27

LAURA

Phase 3 Active not recruiting

216 enrolled 25 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT03940703 2026-02-27

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Phase 2 Active not recruiting

140 enrolled 47 charts

Carcinoma, Non-Small-Cell Lung

NCT04606771 2026-02-27

CoC

Phase 2 Active not recruiting

30 enrolled 20 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03778229 2026-02-10

SAVANNAH

Phase 2 Active not recruiting

367 enrolled 32 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03133546 2026-02-06

BOOSTER

Phase 2 Completed

155 enrolled 23 charts

Non Small Cell Lung Cancer Metastatic

NCT04487080 2026-02-04

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT02411448 2026-01-16

RELAY

Phase 3 Active not recruiting

545 enrolled 24 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT04765059 2026-01-13

COMPEL

Phase 3 Active not recruiting

98 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT02296125 2026-01-09

FLAURA

Phase 3 Completed

674 enrolled 21 charts 2 FDA

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT02442349 2026-01-09

AURA17

Phase 2 Completed

171 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT02157883 2025-11-19

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

Phase 1 Completed

39 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05215951 2025-10-15

MINOVA

Phase 2 Terminated

4 enrolled 9 charts

Lung Neoplasms

NCT04035486 2025-10-10

FLAURA2

Phase 3 Active not recruiting

587 enrolled 44 charts 2 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT03414814 2025-02-11

Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation

Phase 2 Completed

15 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT02841579 2025-01-28

AZENT

Phase 2 Completed

22 enrolled 26 charts

Carcinoma, Non-Small-Cell Lung

NCT02151981 2025-01-07

AURA3

Phase 3 Completed

421 enrolled 18 charts

Anticancer Treatment

NCT02094261 2024-11-06

AURA2

Phase 2 Completed

210 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03239340 2024-10-21

ELIOS

Phase 2 Completed

154 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02454933 2024-09-19

CAURAL

Phase 3 Completed

29 enrolled 10 charts

Locally Advanced or Metastatic EGFR T790M+ NSCLC

NCT02954523 2024-07-05

Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Phase 1/2 Terminated

10 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02759835 2024-06-07

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

Phase 2 Completed

37 enrolled 23 charts

Adenocarcinoma of Lung, Lung Neoplasms

NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Phase 3 Terminated

8 enrolled 7 charts

NSCLC

NCT04816214 2024-03-05

GEOMETRY-E

Phase 3 Terminated

6 enrolled 20 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT02789345 2024-02-05

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Phase 1 Completed

29 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT02163733 2024-01-22

Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer

Phase 1 Completed

38 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01802632 2024-01-18

AURA

Phase 1/2 Completed

603 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT03434418 2023-10-17

A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

Phase 2 Completed

17 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT02803203 2023-09-22

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

Phase 1/2 Completed

49 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03989115 2023-06-26

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Phase 1/2 Completed

113 enrolled 22 charts

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Noonan Syndrome, Ovarian Neoplasms, Pancreatic Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT04179890 2023-05-25

UpSwinG

462 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT03455829 2023-05-06

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

Phase 1/2 Completed

30 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03463525 2023-01-27

ODIN-BM

Phase 1 Completed

4 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT03255083 2022-01-19

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Phase 1 Terminated

13 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT03853551 2021-06-03

Osimertinib Study in Indian Patients

Phase 4 Completed

60 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung

NCT03370770 2020-12-24

Afatinib Osimertinib Sequencing NIS

204 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT02529995 2020-02-11

AURAChinaPK

Phase 1 Completed

31 enrolled 22 charts

Carcinoma

NCT02179671 2019-08-02

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Phase 2 Completed

32 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02491944 2016-10-13

A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291

Phase 1 Completed

27 enrolled 21 charts

Neoplasms